Skip to main content

Living autologous heart valves for minimally invasive implantable procedures

Ziel

Cardiovascular disease still represents the Killer No.1 in the EU accounting for substantial morbidity/mortality and health care cost. Heart valve replacement represents the most common surgical therapy for valvular heart disease with almost 200.000 annual implantations worldwide. Currently, heart valve prosthesis-associated problems occur in 30-35% of patients within 10 years, frequently necessitating risky re-operations. A particularly severe problem relates to children with congenital heart defects (1% of all newborns) who cannot be treated efficiently due to the lack of growths of the clinically available “artificial” valve prostheses. The principal objective of the LifeValve project is to develop a new therapeutic strategy to treat heart valve disease patients more efficiently. Two novel life science technologies will be combined: tissue engineering and minimally invasive implantation technology. In particular, the scientific and technological approach of the LifeValve project is to develop a clinically relevant tissue engineered living heart valve, with the capacity of regeneration and growths which can be implanted by minimally invasive catheter technology. First clinical trials will be enrolled in paediatric patients addressing the currently unmet dramatic medical need for growing implants. A highly interdisciplinary approach combines basic sciences, medical research, engineering and clinical practice. In addition, close industry-academia collaborations are integrated. It is expected that new knowledge applicable for a much broader field of cardiovascular diseases will be generated by the unique combination of consortium partners each representing opinion leaders in their fields. The consortium is compact comprising all the necessary expertise and skills to realize the precisely planned work in a short period of time.The close collaboration of the well interconnected LifeValve consortium will most efficiently contribute to an added value for the EU.

Aufforderung zur Vorschlagseinreichung

FP7-HEALTH-2009-single-stage
Andere Projekte für diesen Aufruf anzeigen

Koordinator

University of Zurich
Adresse
Ramistrasse 71
8006 Zurich
Schweiz
Aktivitätstyp
Higher or Secondary Education Establishments
EU-Beitrag
€ 2 470 000
Kontakt Verwaltung
Simon Philipp Hoerstrup (Prof.)

Beteiligte (7)

DEUTSCHES HERZZENTRUM BERLIN
Deutschland
EU-Beitrag
€ 3 142 372
Adresse
Augustenburger Platz 1
13353 Berlin
Aktivitätstyp
Higher or Secondary Education Establishments
Kontakt Verwaltung
Boris Schmitt (Dr.)
TECHNISCHE UNIVERSITEIT EINDHOVEN
Niederlande
EU-Beitrag
€ 1 784 000
Adresse
Groene Loper 3
5612 AE Eindhoven
Aktivitätstyp
Higher or Secondary Education Establishments
Kontakt Verwaltung
Frank Baaijens (Prof.)
MEDIZINISCHE UNIVERSITAET WIEN
Österreich
EU-Beitrag
€ 215 480
Adresse
Spitalgasse 23
1090 Wien
Aktivitätstyp
Higher or Secondary Education Establishments
Kontakt Verwaltung
Gerald Maurer (Prof.)
pfm Produkte fur die Medizin AG
Deutschland
EU-Beitrag
€ 201 000
Adresse
Wankelstr. 60
50996 Cologne
Aktivitätstyp
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Kontakt Verwaltung
Jens Nikelski (Mr.)
XELTIS AG
Schweiz
EU-Beitrag
€ 850 500
Adresse
Muhlebachstrasse 26
8008 Zurich
Aktivitätstyp
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Kontakt Verwaltung
René Stenger (Mr.)
XELTIS BV
Niederlande
EU-Beitrag
€ 1 146 000
Adresse
De Lismortel R2 06 Cat Build 31
5612 AR Eindhoven
Aktivitätstyp
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Kontakt Verwaltung
Martijn Cox (Mr.)
DEBRECENI EGYETEM
Ungarn
EU-Beitrag
€ 67 000
Adresse
Egyetem Ter 1
4032 Debrecen
Aktivitätstyp
Higher or Secondary Education Establishments
Kontakt Verwaltung
Laszlo Balkay (Dr.)